Literature DB >> 24576164

The state of the union on treatment of acute myeloid leukemia.

Ashkan Emadi1, Judith E Karp.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24576164     DOI: 10.3109/10428194.2014.897705

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

1.  Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells.

Authors:  Brandon A Carter-Cooper; Steven Fletcher; Dana Ferraris; Eun Yong Choi; Dahlia Kronfli; Smaraki Dash; Phuc Truong; Edward A Sausville; Rena G Lapidus; Ashkan Emadi
Journal:  Bioorg Med Chem Lett       Date:  2016-11-17       Impact factor: 2.823

2.  Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; Matthew C Foster; E Claire Dees; Gary Smith; S Percy Ivy; Pamela Harris
Journal:  J Natl Cancer Inst       Date:  2015-11-09       Impact factor: 13.506

3.  Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Authors:  Rena G Lapidus; Brandon A Carter-Cooper; Mariola Sadowska; Eun Yong Choi; Omasiri Wonodi; Nidal Muvarak; Karthika Natarajan; Lakshmi S Pidugu; Anil Jaiswal; Eric A Toth; Feyruz V Rassool; Arash Etemadi; Edward A Sausville; Maria R Baer; Ashkan Emadi
Journal:  Pharmaceuticals (Basel)       Date:  2016-01-19

4.  Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.

Authors:  Ashkan Emadi; Najeebah A Bade; Brandi Stevenson; Zeba Singh
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.